Plain-English translation of NCT04865939 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
When doctors remove cancer from the upper urinary tract (kidney or ureter), there is a significant risk that cancer cells may travel to the bladder and cause new tumors there. This trial is testing whether using —a chemotherapy medication instilled directly into the bladder during surgery—works better than using continuous sterile water irrigation to wash out cancer cells and prevent this recurrence.
After surgery to remove upper urinary tract cancer, up to half of patients develop bladder cancer, likely because tumor cells shed during surgery travel downstream and implant in the bladder. This study aims to find the most effective method to reduce this serious complication.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will undergo surgery to remove your upper urinary tract cancer. During the operation, you will randomly receive one of two treatments: either a chemotherapy medication instilled into your bladder and allowed to stay there for 1–3 hours, or continuous flushing of your bladder with sterile water for 1–3 hours. After surgery, you will be followed to monitor whether bladder cancer develops and to track any side effects from the treatment.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States